OrbiMed’s Medtronic MDT Stock Holding History

OrbiMed’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-695,707	Closed	-$54.3M	–	143
2015 Q1	$54.3M	Buy	+695,707	New	+$52.7M	0.46%	56

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

OrbiMed's MDT Position: Q1 2018 in Review

OrbiMed sold out of Medtronic (MDT) in Q1 2018, closing a stake of 254,200 shares — an estimated $20.5M sold.

OrbiMed first reported a position in MDT in Q2 2013 and held it in 18 quarters. The position peaked at $78M in Q2 2017. 1,381 funds tracked by Wall St. Rank hold MDT as of Q1 2018.

OrbiMed reported no remaining Medtronic position as of Q1 2018 after selling out during the quarter.
OrbiMed sold 254,200 Medtronic shares in Q1 2018, an estimated $20.5M.
OrbiMed first reported a position in Medtronic in Q2 2013 and held it in 18 quarters.
OrbiMed's Medtronic position peaked at $78M in Q2 2017.
1,381 funds tracked by Wall St. Rank held Medtronic as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.